MAFTicagrelor Tablet 90 mg
Prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in adults with acute coronary syndromes, that is, people:
• with ST-segment-elevation myocardial infarction (STEMI); or
• with non-ST-segment-elevation myocardial infarction (NSTEMI); or
• with unstable angina requiring hospitalisation – defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the following characteristics:
– age 60 years and older;
– previous myocardial infarction;
– previous coronary artery bypass grafting (CABG);
– coronary artery disease with stenosis of 50% or more in at least two vessels;
– previous ischaemic stroke;
– previous transient ischaemic attack;
– carotid stenosis of at least 50%;
– cerebral revascularisation;
– diabetes mellitus;
– peripheral arterial disease; or
– chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73m2 of body surface area.
Ticagrelor should be used in combination with low-dose aspirin for up to 12 months.